Novartis granted priority review for everolimus in advanced kidney cancer « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Novartis granted priority review for everolimus in advanced kidney cancer

Posted on September 9, 2008 by crimsoncanary

Novartis have announced that RAD001 (everolimus) has been granted priority review by the US FDA for the treatment of patients with advanced kidney cancer after failure of standard treatment. Marketing authorization applications for RAD001 have also been filed with the EMEA and Swissmedic. The proposed brand name for RAD001 is Afinitor

Filed under: kinase | Tagged: Afinitor, everolimus, kinase, mTOR, Novartis, RAD-001, RAD001, regulatory

« Sirolimus found to cause veno-occlusive disease (VOD) Boehringer Ingelheim publish 3 papers on Inducible T-Cell Kinase (Itk) inhibitors »